astrazeneca q4 2024 - Search News

AstraZeneca shares rise

AstraZeneca gains as Q4 results clear China overhang

AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation. Read more here.

Pharmaceutical Technology on M… · 1d

AstraZeneca’s shares rise as it addresses China investigation

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).

Reuters · 2d

AstraZeneca shares rise as China probe update reassures

AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes for two cancer drugs, reassuring analysts and investors that the business impact would be minor.

The Financial Times · 2d

AstraZeneca sales jump despite troubles in China

UK drugmaker AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter of 2024. AstraZeneca ’s $14.

AstraZeneca PLC (AZN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges

AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic ...

1don MSN

AstraZeneca outlines $3.2 dividend hike and anticipates strong 2025 growth

Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline ...

BioSpace2d

AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript

Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants ...

AstraZeneca reports Q4 core EPS $2.09, up 49% at CER

Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...

1don MSN

Why AstraZeneca Topped the Market on Thursday

AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...

precisionmedicineonline1d

AstraZeneca Optimistic About Phase III Capivasertib Data in 2025, Reports Strong Q4 Product Growth

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

1don MSN

AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Call Transcript

Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...

AstraZeneca reports Q4 core EPS $2.09

Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results